KIORA PHARMACEUTICALS INC

Listed Company

KPRXCIK 0001372514NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

Net Income

$-10.84M

Total Assets

$24.25M

Equity

$16.13M

Shares Out

3.95M

Op. Cash Flow

$-9.96M

Business

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of retinal diseases. Its main product candidates include KIO-301, a small-molecule photoswitch for vision restoration in retinitis pigmentosa, KIO-104, an intravitreal DHODH inhibitor for retinal inflammatory diseases, and KIO-101, a topical DHODH formulation for ocular autoimmune presentations. The company operates as a single operating segment focused on research, clinical development and intellectual property management, while pursuing strategic partnerships and licensing. It advances clinical programs and regulatory filings in the U.S., Europe and other regions and plans commercialization through collaborators and potential direct physician-facing channels globally.

Summary from filing dated 2025-03-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration Revenue	0	16	0	—	—
Grant Revenue	0	20,000	0	—	—
Total Revenue	0	16	0	—	—
General and Administrative	6	6	5	8	5
Research and Development	11	8	4	3	5
Collaboration Credits	−7	−3	0	—	—
In-Process R&D Impairment	5	2	2	0	—
Change in Fair Value of Contingent Consideration	−1	−937,469	2	582,605	−475,956
Total Operating Expenses	13	12	13	12	14
Operating (Loss) Income Before Other Income (Expense), Net	−13	5	−13	−12	−14
Impairment of Intangible Assets	0	−104,167	0	—	—
Loss on Disposal of Fixed Assets	0	−3,859	−28,379	4,211	—
Interest Income	894,002	1	173,989	56,891	1,141
Interest Expense	−19,960	−21,446	−11,132	—	—
Other (Expense) Income, Net	−160,272	26,073	28,841	−14,498	—
Total Other Income, Net	713,770	1	163,319	−1	272,480
(Loss) Income Before Income Tax Expense	−12	6	−12	−14	−14
Income Tax Benefit (Expense)	1	−2	−100,000	113,010	192,603
Net (Loss) Income	−11	4	−13	−14	−14
Net (Loss) Income Attributable to Common Shareholders, basic	−11	4	—	—	—
Net (Loss) Income Attributable to Common Shareholders, diluted	−11	4	—	—	—
Net (Loss) Income per Common Share - Basic (in usd per share)	−2.6	0.93	−24.25	−18.55	−57.12
Weighted Average Shares Outstanding - Basic (in shares)	4	4	538,007	732,303	241,099
Net (Loss) Income per Common Share - Diluted (in usd per share)	−2.64	0.87	−24.25	−18.55	−57.12
Weighted Average Shares Outstanding - Diluted (in shares)	4	4	538,007	732,303	241,099
Unrealized (Loss) Gain on Marketable Securities	−20,073	29,719	0	—	—
Foreign Currency Translation Adjustments	56,096	−129,077	−60	−96,310	−85,629
Comprehensive (Loss) Income	−11	3	−13	−14	−14

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and Cash Equivalents	9	4	2	6	8
Short-Term Investments	8	23	0	—	—
Prepaid Expenses and Other Current Assets	1	2	233,382	343,069	606,520
Collaboration Receivables	2	601,197	0	—	—
Tax and Other Receivables	2	270,246	—	—	—
Prepaid Collaboration Expenses	201,332	0	—	—	—
Total Current Assets	22	30	5	8	9
Property and Equipment, Net	91,672	5,232	8,065	55,177	73,999
Restricted Cash	4,600	4,100	4,300	49,300	45,000
Intangible Assets and In-Process R&D, Net	2	7	9	11	11
Operating Lease Assets with Right-of-Use	285,827	57,170	106,890	116,992	209,411
Other Assets	59,687	24,913	40,767	33,000	42,964
Total Assets	24	36	14	19	20
Accounts Payable	1	415,590	206,260	1	160,621
Accrued Expenses	2	5	1	2	1
Accrued Collaboration Credit	0	981,111	—	—	—
Operating Lease Liabilities	164,461	23,355	47,069	105,782	118,846
Total Current Liabilities	4	6	2	3	2
Contingent Consideration	3	4	5	3	3
Deferred Tax Liability	102,152	490,690	779,440	689,121	802,131
Deferred Collaboration Revenue	1	0	—	—	—
Non-Current Operating Lease Liabilities	203,798	33,815	59,822	0	90,566
Total Non-Current Liabilities	4	5	6	4	4
Total Liabilities	8	11	8	7	6
Commitments and Contingencies (Note 12)	—	—	—	—	—
Preferred stock	4	4	4	0	0
Common stock	275,289	267,679	77,078	17,986	3,166
Additional Paid-In Capital	170	169	153	146	136
Accumulated Deficit	−154	−143	−147	−134	−121
Accumulated Other Comprehensive Loss	−246,137	−282,159	−182,801	−182,741	−86,431
Total Stockholders Equity	16	26	6	11	15
Total Liabilities and Stockholders Equity	24	36	14	19	20

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and Amortization	24,801	19,205	51,798	41,609	45,296
Reduction of Right-of-Use Assets	186,277	46,500	10,626	92,419	181,977
Stock-Based Compensation	900,236	656,593	754,944	462,450	842,475
Change in Fair Value of Contingent Consideration	−1	−937,469	2	582,605	−505,675
Accretion of Discount on Marketable Securities	−112,305	−283,474	0	—	—
Change in Accrued Interest on Marketable Securities	164,534	−25,811	0	—	—
Net Realized Gain on Marketable Securities	−2,371	−4,519	0	—	—
Change in Unrealized Gain on Cash Equivalents	−119	119	0	—	—
Deferred Taxes	−388,538	−288,750	90,319	−113,010	−192,603
Loss on Disposal of Assets	0	3,760	28,379	−4,211	—
Prepaid Expenses and Other Current Assets	419,736	−2	885	275,161	−156,951
Collaboration Receivables	−921,573	−601,197	0	—	—
Tax and Other Receivables	−1	2	−548,109	−872,736	−441,196
Other Assets	−34,172	15,231	−7,583	−22,465	14,111
Accounts Payable	1	226,119	−808,016	782,463	−310,665
Accrued Expenses	−2	3	−459,713	609,719	40,882
Accrued Collaboration Credit	−1	981,111	0	—	—
Operating Lease Liabilities	−103,845	−46,500	584	−103,629	−181,977
Deferred Collaboration Revenue	1	0	—	—	0
Net Cash (Used in) Provided by Operating Activities	−10	9	−10	−10	−11
Purchases of Property and Equipment	−110,789	−6,256	0	0	−63,865
Purchases of Marketable Securities	−8	−36	0	—	—
Sales of Marketable Securities	305,000	1	0	—	—
Maturities of Marketable Securities	22	12	0	—	—
Net Cash Provided by (Used in) Investing Activities	14	−23	0	6,375	−157,020
Gross Proceeds from Private Placement	0	15	200,000	0	—
Issuance Costs for Private Placement	0	−1	—	—	−1
Exercise of Warrants	265,655	2	307,079	520,000	50,001
Proceeds from Line of Credit	3	0	—	—	—
Repayments of Line of Credit	−3	0	—	—	—
Net Cash Provided by Financing Activities	265,655	15	6	9	18
Effect of Exchange Rate Changes on Cash	173,634	−57,231	36,020	−85,037	−81,503
Net Increase in Cash and Cash Equivalents	5	1	−4	−2	7
Creation of Right-of-Use Assets and Related Lease Liabilities	336,507	0	114,747	55,415	313,312
Tenant Improvements Paid Directly by Lessor	72,810	0	—	—	—
Grant of Restricted Stock Awards	431	306	2,701	300	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro